Art

J-GLOBAL ID：201802246635897914   Reference number：18A0289190

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

再発,プラチナ感受性高悪性度卵巣癌(ARIEL2第1報)ルカパリブ:国際的多施設,非盲検,第2相試験【Powered by NICT】

Author (31)： Swisher Elizabeth M (University of Washington, Seattle, WA, USA) ,  Lin Kevin K (Clovis Oncology, Boulder, CO, USA) ,  Oza Amit M (Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada) ,  Scott Clare L (Royal Melbourne Hospital, Melbourne, VIC, Australia) ,  Giordano Heidi (Clovis Oncology, Boulder, CO, USA) ,  Sun James (Foundation Medicine, Cambridge, MA, USA) ,  Konecny Gottfried E (University of California Los Angeles, Santa Monica, CA, USA) ,  Coleman Robert L (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) ,  Tinker Anna V (British Columbia Cancer Agency, Vancouver, BC, Canada) ,  O'Malley David M (The Ohio State University, James Cancer Center, Columbus, OH, USA) ,  Kristeleit Rebecca S (University College London, Cancer Institute, London, UK) ,  Ma Ling (Rocky Mountain Cancer Centers, Lakewood, CO, USA) ,  Bell-McGuinn Katherine M (Memorial Sloan-Kettering Cancer Center, New York, NY, USA) ,  Brenton James D (Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK) ,  Cragun Janiel M (The University of Arizona Cancer Center, Tucson, AZ, USA) ,  Oaknin Ana (Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain) ,  Ray-Coquard Isabelle (GINECO, Centre Leon Berard and University Claude Bernard, Lyon, France) ,  Harrell Maria I (University of Washington, Seattle, WA, USA) ,  Mann Elaina (Clovis Oncology, Boulder, CO, USA) ,  Kaufmann Scott H (Mayo Clinic, Rochester, MN, USA) ,  Floquet Anne (Institut Bergonie, Bordeaux, France) ,  Leary Alexandra (Gustave Roussy Cancer Center and INSERM U981, Villejuif, France) ,  Harding Thomas C (Clovis Oncology, Boulder, CO, USA) ,  Goble Sandra (Clovis Oncology, Boulder, CO, USA) ,  Maloney Lara (Clovis Oncology, Boulder, CO, USA) ,  Isaacson Jeff (Clovis Oncology, Boulder, CO, USA) ,  Allen Andrew R (Clovis Oncology, Boulder, CO, USA) ,  Rolfe Lindsey (Clovis Oncology, Boulder, CO, USA) ,  Yelensky Roman (Foundation Medicine, Cambridge, MA, USA) ,  Raponi Mitch (Clovis Oncology, Boulder, CO, USA) ,  McNeish Iain A (Institute of Cancer Sciences, University of Glasgow, Glasgow, UK)
Material： Lancet Oncology  (Lancet Oncol)
Volume： 18  Issue： 1  Page： 75-87  Publication year： 2017 
JST Material Number： W1266A  ISSN： 1470-2045  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Poly(ADP-ribose) polymerase (P...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A0289190&from=J-GLOBAL&jstjournalNo=W1266A") }}

Thesaurus term： tumor cell ,  *recurrence ,  anemia ,  somatic cell ,  *sensitivity ,  United States of America ,  variation(biology) ,  hospital ,  therapy ,  wild type ,  *phase 2 study ,  patient ,  hemoglobin ,  genome ,  *ovarian tumor

JST classification (1)： Treatment for tumors in general  (GE03031L)

Terms in the title (9)： 再発 ,  プラチナ ,  感受性 ,  悪性度 ,  卵巣癌 ,  ルカパリブ ,  施設 ,  盲 ,  第2相試験